Category: Rhythmia Medical Inc.
Boston Scientific agrees to pay up to $265 million for Rhythmia Medical and its heart-mapping technology
Boston Scientific (NYSE:BSX) said it's agreed to pony up $90 million in cash and perhaps another $175 million to acquire Rhythmia Medical and its heart-mapping technology.
A look back at last week's Heart Rhythm Society meeting, which put the spotlight on Cameron Health's "leadless" defibrillator, Boston Scientific's Watchman heart implant, Topera Medical's rotor-mapping technology and St. Jude Medical's recalled Riata defibrillator leads.
More than 35,000 physicians, allied healthcare providers and industry representatives descended on the cavernous convention center in Boston's up-and-coming Seaport section for the Heart Rhythm Society's annual meeting.
In its quest to become a larger player in the global medical device market, Samsung Electronics Co. Ltd. creates a new brand to represent its collaboration with Korea-based diagnostic ultrasound equipment maker Medison Co.: Samsung Medison Co. Ltd.
Samsung Electronics Co. Ltd. (KSE:005930.KS) launched a new corporate identity for medical products created through its collaboration with Korea based ultrasound equipment maker Medison Co.
The combined group, Samsung Medison, has a goal of becoming one of the world's top 4 diagnostic ultrasound firms and, by 2020, aims to have 10,000 employees, according to the company.
New study shows that Masimo Corp.'s noninvasive SpCO technology is effective for screening emergency department patients for carbon monoxide poisoning.
Masimo Corp. (NSDQ:MASI) announced positive results from a study on its carbon monoxide (CO) poisoning screening technology.
The Irvine, Calif.-based company reported that an independent study demonstrated that noninvasive Masimo carboxyhemoglobin (SpCO) measurements provide an "effective means for screening at-risk populations for CO poisoning" with "acceptable bias and precision" compared to invasive blood gas analysis. The results were published in the April issue of Annals of Emergency Medicine.
Burlington, Mass.-based Rhythmia Medical Inc. has raised $5 million of a hoped-for $7 million equity round from eight investors.
Rhythmia Medical Inc. drummed up $5 million in equity from eight investors, according to a Securities & Exchange Commission filing.
The Burlington, Mass.-based developer of medical devices for treating arrhythmia is still $2 million shy of its $7 million target for this funding round, according to the filing.
Rhythmia Medical secures nearly $2.7 million in new equity funding to assist development of its heart-mapping device.
Rhythmia Medical Inc. raised nearly $2.7 million in a third-round equity sale to a group of 14 investors, according to new securities documents.
Burlington, Mass.-based Rhythmia, founded in 2004 by two Israeli entrepreneurs, is developing medical devices able to quickly map the electrical activity of the heart and pinpoint catheter ablation procedures.